Juvenil idiopatik artritli Türk çocukların büyüme parametreleri

Year 2020, Volume: 45 Issue: 2, 495 - 501, 30.06.2020

Sibel Balcı , Mehmet Çalkan , Semine Özdemir , Dilek Doğruel Derya Altintas , Rabia Miray Kisla Ekinci

https://doi.org/10.17826/cumj.675982

Cited By: 1

Abstract

Amaç: Juvenil idiopatik artrit (JIA) çocukluk çağında en sık görülen romatizmal hastalıktır ve büyüme geriliği ile sonuçlanabilmektedir. Bu çalışma ile JIA’lı Türk çocuklarında büyüme parametrelerini araştırmayı amaçladık.
Gereç ve Yöntem: Juvenil idiopatik artrit tanılı 233 hastanın klinik ve laboratuvar verileri, vücut ağırlığı, boy ve vücut kitle indeksi (VKI) bilgileri hastaların tıbbi dosyalarından geriye dönük elde edildi. Büyüme verileri ve z-skorları Türk çocuklarının antropometrik referans değerlerine göre hesaplandı. Hastalara International League of Associations for Rheumatology sınıflama kriterlerine göre tanı kondu.
Bulgular: Hastaların %59,2’si (sayı, 138) kız hastaydı. Ortalama tanı yaşı 7.40±4,54 yıl ve çalışma esnasında ortalama yaş 11.20±4,45 yıldı. Ortalama ilk vizit vücut ağırlığı ve VKI z-skorları son vizit değerlere göre istatistiksel anlamlı olarak düzeldi. Ortalama ilk vizit boy z-skoru ise istatistiksel anlamlı olarak geriledi. Son vizitte kısa boy sıklığı %7,3 (sayı, 17) idi. Eritrosit çökelme hızı, C-reaktif protein düzeyleri dahil olmak üzere akut faz reaktanları son vizitte ilk vizit değerlerine kıyasla anlamlı olarak düşüktü. Son vizit büyüme parametreleri tanı yaşı, hastalık süresi, remisyon ve relaps durumu, kortikosteroid ve biyolojik ajan kullanımına göre farklılık göstermemekteydi.
Sonuç: JIA hastalarında devam eden inflamasyonun kontrol altına alınması ile vücut ağırlığı ve VKI z-skorları düzelebilir, fakat bu durum boy kısalığını önlemek için yeterli olmayabilir. 

Keywords

Büyüme, çocuk, juvenile idiopatik artrit

Supporting Institution

Yok

Project Number

Yok

Growth parameters of Turkish children with juvenile idiopathic arthritis

Abstract

Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood which could results in growth retardation. With the present study, we aimed to investigate the growth parameters in Turkish children with JIA.
Materials and Methods: Clinical and laboratory data, weight, height, and body mass index of 233 JIA patients were retrospectively collected from medical files. Growth parameters and z-scores were calculated by anthropometric references in Turkish children. The patients were diagnosed according to the International League of Associations for Rheumatology classification criteria.
Results: The frequency of female patients was 59.2% (138). The mean age at diagnosis was 7.40±4.54 years, the mean age at the study time was 11.20±4.45 years. While mean initial visit weight and BMI z-scores were significantly improved at last visit, initial mean height z-score was significantly decreased. The frequency of short stature at last visit was 7.3% (number, 17). Acute phase reactants, including erythrocyte sedimentation rate, C-reactive protein levels were significantly lower at last visit than initial. Last visit growth parameters did not differ according age at diagnosis, disease duration and presence or absence of remission, relapses, corticosteroid usage, and biologic agent usage.
Conclusion: Suppressing ongoing inflammation in JIA patients improves both weight and BMI z-scores of those patients, however, it may be insufficient to prevent short stature. 

Keywords

Growth, children, juvenile idiopathic arthritis

Project Number

Yok

References

• 1- Yilmaz M, Kendirli SG, Altintas DU, Karakoc GB, Inal A, Kilic M. Juvenile idiopathic arthritis profile in Turkish children. Pediatr Int. 2008; 50:154-158.
• 2- Barut K, Adrovic A, Şahin S, Kasapçopur Ö. Juvenile Idiopathic Arthritis. Balkan Med J. 2017; 34: 90-101.
• 3- Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004; 31: 390-392.
• 4- MacRae VE, Wong SC, Farquharson C, Ahmed SF. Cytokine actions in growth disorders associated with pediatric chronic inflammatory diseases (review). Int J Mol Med. 2006;18: 1011-1018.
• 5- Bechtold S, Simon D. Growth abnormalities in children and adolescents with juvenile idiopathic arthritis. Rheumatol Int. 2014; 34: 1483-1488.
• 6- Wallace CA, Ruperto N, Giannini E; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study Group. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol. 2004; 31: 2290-2294.
• 7- Neyzi O, Gunoz A, Furman A, et al. Türk Çocuklarında vücut ağırlığı, boy uzunluğu, baş çevresi ve vücut kitle indeksi referans değerleri. Çocuk Sağlığı ve Hastalıkları Derg 2008; 51: 1-14.
• 8- Balci S, Ekinci RMK, Bayazit AK, et al. Juvenile systemic lupus erythematosus: a single-center experience from southern Turkey. Clin Rheumatol. 2019; 38: 1459-1468.
• 9- Kişla Ekinci RM, Balci S, Akay E, Doğruel D, Altintaş DU, Yilmaz M. Disease Severity and Genotype Affect Physical Growth in Children with Familial Mediterranean Fever. Arch Rheumatol. 2019; 34: 288-293.
• 10- Gaspari S, Marcovecchio ML, Breda L, Chiarelli F. Growth in juvenile idiopathic arthritis: the role of inflammation. Clin Exp Rheumatol. 2011; 29: 104-110.
• 11- De Benedetti F, Brunner H, Ruperto N, et al. Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: results from a phase III trial. Arthritis Rheumatol. 2015; 67: 840-848.
• 12- Kearsley-Fleet L, Hyrich KL, Davies R, Lunt M, Southwood TR; British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Growth in children and adolescents with juvenile idiopathic arthritis over 2 years of treatment with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Rheumatology (Oxford). 2015; 54: 1279-1285.
• 13- McErlane F, Carrasco R, Kearsley-Fleet L, et al. Growth patterns in early juvenile idiopathic arthritis: Results from the Childhood Arthritis Prospective Study (CAPS). Semin Arthritis Rheum. 2018; 48: 53-60.
• 14- Guzman J, Kerr T, Ward LM, et al. Growth and weight gain in children with juvenile idiopathic arthritis: results from the ReACCh-Out cohort. Pediatr Rheumatol Online J. 2017; 15: 68.
• 15- Miyamae T, Yokoya S, Yamanaka H, Yokota S. Effect of tocilizumab on growth impairment in systemic juvenile idiopathic arthritis with long-term corticosteroid therapy. Mod Rheumatol. 2014; 24: 567-571.
• 16- Simon D, Fernando C, Czernichow P, Prieur AM. Linear growth and final height in patients with systemic juvenile idiopathic arthritis treated with long-term glucocorticoids. J Rheumatol. 2002; 29: 1296-300.
• 17- Padeh S, Pinhas-Hamiel O, Zimmermann-Sloutskis D, Berkun Y. Children with oligoarticular juvenile idiopathic arthritis are at considerable risk for growth retardation. J Pediatr. 2011; 159: 832-837.e1-2.
• 18- Uettwiller F, Perlbarg J, Pinto G, et al. Effect of biologic treatments on growth in children with juvenile idiopathic arthritis. J Rheumatol. 2014; 41: 128-135.
• 19- Schmeling H, Seliger E, Horneff G. Growth reconstitution in juvenile idiopathic arthritis treated with etanercept. Clin Exp Rheumatol. 2003; 21: 779-784.
• 20- Billiau AD, Loop M, Le PQ, Berthet F, Philippet P, Kasran A, Wouters CH. Etanercept improves linear growth and bone mass acquisition in MTX-resistant polyarticular-course juvenile idiopathic arthritis. Rheumatology (Oxford). 2010; 49: 1550-1558.
• 21- Giannini EH, Ilowite NT, Lovell DJ, et al. Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2010; 62: 3259-3264.